1. Abbatt JD (1953) Experiences of management and treatment of polycythemia vera using p32 as a therapeutic weapon. J Fac Radiol 5(2):141–147
2. Barone R, Borson-Chazot FO, Valkerna R, Walrand S, Chauvin F, Gogou L, Kvols LK, Krenning EP, Jamar F, Pauwels S (2005) Patient-specific dosimetry in predicting renal toxicity with Y-90-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 46:99S–106S
3. Bombardieri E, Aktolun C, Baum RP, Bishof-Delaloye A, Buscombe J, Chatal JF, Maffioli L, Moncayo R, Mortelmans L, Reske SN (2003) I-131/I-123-metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 30(12):BP132–BP139
4. Carrasquillo JA, Pandit-Taskar N, Chen CC (2012) Radionuclide therapy of adrenal tumors. J Surg Oncol 106(5):632–642
5. Ezziddin S, Lohmar J, Yong-Hing CJ, Sabet A, Ahmadzadehfar H, Kukuk G, Biersack HJ, Guhlke S, Reichmann K (2012) Does the pretherapeutic tumor SUV in Ga-68 DOTATOC PET predict the absorbed dose of Lu-177 octreotate? Clin Nucl Med 37(6):E141–E147